SOHO 2024 | The current state of the art in Ph+ ALL and future outlooks
Partow Kebriaei, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses advances in the treatment of patients with Ph-positive acute lymphoblastic leukemia (Ph+ ALL), highlighting the effectiveness of chemotherapy-free approaches. This may potentially eliminate the need for cytotoxic chemotherapy or stem cell transplantation (SCT) in some patients. Dr Kebriaei notes that while some high-risk subsets may still benefit from SCT, ongoing studies like the GRAAPH-2024 trial will provide more insights. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
